Fundraising Fox
/Companies
Sign in

CellRep

Founded 2024 · 10 employees on LinkedIn · 4 known investors

Find your way into CellRep

Sign up to see every warm intro you have to CellRep

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the CellRep team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CellRep develops an AI-powered platform that discovers small molecules to reprogram exhausted immune cells, enhancing their function for therapeutic applications including cancer immunotherapy and chronic viral infections. The company's compounds act on multiple biological layers to restore cellular performance without genetic modification.

AI & Machine LearningBiotechLongevity

Founders & leadership

CellRep was founded in 2024 by Alfonso Amat, Federico Perdomo Celis, Manuel Franco Cortés, and Julian Ganzabal.

AAAlfonso Amat
Alfonso AmatCEO & Co-FounderAlfonso Amat is CEO and co-founder of CellRep, a company developing an AI-powered platform to discover small molecules that reprogram immune cells for therapeutic applications in cancer immunotherapy and chronic viral infections.
FPFederico Perdomo Celis
Federico Perdomo CelisCSO & Co-FounderFederico Perdomo Celis holds an MD and PhD in Immunology, with over a decade of research experience studying T cell responses in chronic viral infections including HIV and hepatitis B, and in cancer. He is Chief Scientific Officer and co-founder of CellRep.
MFManuel Franco Cortés
Manuel Franco CortésCCO & Co-Founder
JGJulian Ganzabal
Julian GanzabalCAIO & Co-FounderJulian Ganzabal is Chief AI Officer and Co-Founder of CellRep, an AI-driven drug discovery platform targeting immune cell reprogramming for cancer and viral therapies. He has worked as a machine learning engineer and teaches deep learning at ITBA.

Investors · 4

GRIDXlisted by GRIDXBuenos Aires · $250K

How we know: GRIDX's portfolio page · Not right? Tell us

NXTPreportedBuenos Aires · $500K – $5M

How we know: a partner's Signal profile · Not right? Tell us

Riverwood CapitalreportedMenlo Park · $25M – $250M

How we know: a partner's Signal profile · Not right? Tell us

Frequently asked questions

What does CellRep do?
CellRep develops an AI-powered platform that discovers small molecules to reprogram exhausted immune cells, enhancing their function for therapeutic applications including cancer immunotherapy and chronic viral infections. The company's compounds act on multiple biological layers to restore cellular performance without genetic modification.
Who founded CellRep?
CellRep was founded by Alfonso Amat, Federico Perdomo Celis, Manuel Franco Cortés, Julian Ganzabal in 2024.
Who are CellRep's investors?
CellRep's investors include AIR Capital, GRIDX, NXTP, Riverwood Capital.